7436-22-8

Basic information

• Product Name: METHYL-D3-AMINE HYDROCHLORIDE
• Synonyms: METHYL-D3-AMINE HCL;METHYL-D3-AMINE HYDROCHLORIDE;METHYL-D3-AMMONIUM CHLORIDE;METHYLAMINE-D3 HYDROCHLORIDE;(2H3)methylammonium chloride;METHYL-D3-AMINE HYDROCHLORIDE, 99 ATOM % D;Methyl-D3-amineCl;Methan-d3-amine hydrochloride
• CAS NO: 7436-22-8
• Molecular Formula: CH₆N*Cl
• Molecular Weight: 70.54
• EINECS: 231-089-6
• Product Categories: Aliphatics;Amines;Isotope Labelled Compounds
• Mol File: 7436-22-8.mol
• Article Data: 17

Chemical Properties

• Melting Point: 232-234 °C(lit.)
• Appearance: /
• Vapor Pressure: 3970mmHg at 25°C
• CAS DataBase Reference: METHYL-D3-AMINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL-D3-AMINE HYDROCHLORIDE(7436-22-8)
• EPA Substance Registry System: METHYL-D3-AMINE HYDROCHLORIDE(7436-22-8)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 7436-22-8(Hazardous Substances Data)

Usage

Chemical Properties

white crystalline powder

Uses

MethylaMine-d3 Hydrochloride is useful in preparation of deuterated diphenylurea derivatives as phosphokinase inhibitors.

InChI:InChI=1/CH5N.ClH/c1-2;/h2H2,1H3;1H/i1D3;

Upstream product

• 593-51-1 methylamine hydrochloride 
• 122025-10-9 C₈H₈⁽²⁾H₃N*ClH 
• 13031-32-8 nitromethane-d3 
• 1221168-47-3 (N-(methyl-d3))-isoindole-1,3-dione instead of 2-(N-(methyl-d3))-isoindole-1,3-dione 
• 85894-44-6 N-Nitroso-N-methyl-d₃-methoxymethylamine 

Downstream Products

• 3669-71-4 N-(methyl-d3)acetamide 
• 1189858-48-7 4-chloropyridinyl-2-(N-1',1',1'-trideuteromethylcarboxamide) 
• 1609392-27-9 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d₃)pyridazine-3-carboxamide 
• 144601-75-2 N-trideuteriomethyl-benzamide 
• 1126623-89-9 C₂₂H₁₅⁽²⁾H₃N₄OS 
• 1443331-82-5 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-trideuteriomethylbenzamide 

Relevant articles and documents

A Small Lattice Change Induces Significant Dynamic Changes of CH3NH3+ Caged in Hybrid Perovskite Crystals: Toward Understanding the Interplay between Host Lattices and Guest Molecules

Two perovskite-type compounds, (MA)2[B′Co(CN)6] (MA = methylammonium, B′ = K(I) and Na(I)), have very similar structures, but exhibit marked differences in the phase and dielectric transitions. Solid state 2H NMR studies reveal the detailed dynamic changes of the caged methylammonium (MA) cations before and after the phase transitions, which are correlated with the different dielectric states of the compounds. Using solid state 59Co NMR, the dynamic changes of the host lattices before and after the transitions, which accompany the changes in the dynamics of the caged MA cations, are unveiled, demonstrating the intriguing interplay between the MA cations and the host lattices. On the basis of these observations, the molecular origins of the dielectric transitions are discussed in detail.

Method for synthesizing deuterated methylamine hydrochloride and deuterated dimethylamine hydrochloride from benzylamine protected by Boc

The invention discloses a method for synthesizing deuterated methylamine hydrochloride and deuterated dimethylamine hydrochloride by using Boc-protected benzylamine. The method mainly comprises the following step: reacting Boc-protected benzylamine serving as a raw material with a deuteration methylation reagent under alkaline conditions to generate deuterated methylamine hydrochloride and deuterated dimethylamine hydrochloride. The synthesis method provided by the invention can avoid the disadvantage that trisubstituted and tetrasubstituted methyl byproducts are easy to generate in the conventional synthesis method. Therefore, the method for preparing the deuterated methylamine hydrochloride and the deuterated dimethylamine hydrochloride has the advantages of few byproducts and easiness in purification, and has important guidance value for research and development and synthesis of deuterated drugs.

Deuterated compound and application thereof in treatment of cancer

The present invention relates to a deuterated compound and application thereof in the treatment of cancer. Specifically, the present invention provides the compound of formula (I) and pharmaceuticallyacceptable salt or ester thereof, and a pharmaceutical composition thereof. The compound and the pharmaceutical composition are used for inhibiting or regulating the activity of tyrosine kinase and treating disease symptoms or symptoms including cancer mediated by tyrosine kinase.